Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. by Paik, David T et al.
UC Office of the President
Recent Work
Title
Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of 
Personalized Cardiovascular Drugs and Therapeutics.
Permalink
https://escholarship.org/uc/item/4t98w2xd
Journal
Pharmacological reviews, 72(1)
ISSN
0031-6997
Authors
Paik, David T
Chandy, Mark
Wu, Joseph C
Publication Date
2020
DOI
10.1124/pr.116.013003
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1521-0081/72/1/320–342$35.00 https://doi.org/10.1124/pr.116.013003
PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:320–342, January 2020
Copyright © 2019 The Author(s).
This is an open access article distributed under the CC BY Attribution 4.0 International license.
ASSOCIATE EDITOR: ELIOT H. OHLSTEIN
Patient and Disease–Specific Induced Pluripotent Stem
Cells for Discovery of Personalized Cardiovascular
Drugs and Therapeutics
David T. Paik, Mark Chandy, and Joseph C. Wu
Stanford Cardiovascular Institute, Stanford University, Stanford, California
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321
II. Induced Pluripotent Stem Cells: A Platform for Precision Medicine . . . . . . . . . . . . . . . . . . . . . . . . . 322
III. Generation of Cardiac Muscle Cells from Induced Pluripotent Stem Cells . . . . . . . . . . . . . . . . . . . 323
A. Induced Pluripotent Stem Cell–Derived Cardiomyocyte Differentiation . . . . . . . . . . . . . . . . . . 323
B. Strategies to Generate Induced Pluripotent Stem Cell–Derived Cardiomyocyte
Subtypes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 323
C. Challenges in Induced Pluripotent Stem Cell–Derived Cardiomyocyte Maturation . . . . . . . 324
1. Cellular Morphology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
2. Contractility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
3. Sarcomeric Protein Isoforms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
4. Mitochondrial Function and Metabolism. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
D. Approaches to Enhance Induced Pluripotent Stem Cell–Derived Cardiomyocyte
Maturation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
IV. Generation of Vascular Cells from Human Induced Pluripotent Stem Cells. . . . . . . . . . . . . . . . . . 326
A. Endothelial and Smooth Muscle Cell Differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
B. Applications of Induced Pluripotent Stem Cell–Derived Vascular Cells . . . . . . . . . . . . . . . . . . 327
V. Strategies for Induced Pluripotent Stem Cell–Based Drug Discovery and Testing. . . . . . . . . . . . 327
A. Methods for Cardiovascular Drug Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
1. Tissue-Specific Response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
2. Organ-on-a-Chip for Optimizing Therapy and Screening Side Effects . . . . . . . . . . . . . . . . . 328
3. Precision Therapies Using Induced Pluripotent Stem Cells . . . . . . . . . . . . . . . . . . . . . . . . . . 328
4. Predicting Responders and Nonresponders to Avoid Trial and Error . . . . . . . . . . . . . . . . . 328
5. Optimizing Clinical Trials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329
B. Strategies for Induced Pluripotent Stem Cell–Based Drug Discovery . . . . . . . . . . . . . . . . . . . . 329
1. In Silico Prediction for Candidate Drugs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329
2. Repurposing Drugs for Cardiovascular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329
3. Screening Novel Compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330
C. Challenges of Implementing Pluripotent Stem Cell Platforms in Industry . . . . . . . . . . . . . . . 330
VI. Cancer Therapy–Induced Cardiotoxicity Screening. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
A. Doxorubicin-Induced Cardiotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
B. Tyrosine Kinase Inhibitor–Induced Cardiotoxicity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332
C. Human Epidermal Growth Factor Receptor Inhibitor–Induced Cardiotoxicity . . . . . . . . . . . . 332
VII. Therapeutics for Cardiac Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
Address correspondence to: Dr. Joseph C. Wu, Stanford Cardiovascular Institute, Stanford University, 265 Campus Drive G1120B,
Stanford, CA 94305. E-mail: joewu@stanford.edu
This work was supported by National Institutes of Health [Grant T32 EB009035 (to D.T.P.)]; University of Toronto Clinician Investigator
Program and Clinician Scientist Training Program and Detweiler Traveling Fellowship from the Royal College of Physicians and Surgeons (to
M.C.); and National Institutes of Health [Grants R01 HL141851, R01 HL141371, R01 HL146690, R01 HL145676, and P01 HL141084] and
Burroughs Wellcome Fund Grant 1015009 (to J.C.W.). Conflict of interest: J.C.W. is a cofounder of Khloris Biosciences but has no competing
interests, as the work presented here is completely independent. The other authors report no conflicts.
https://doi.org/10.1124/pr.116.013003.
320
A. Arrhythmia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 333
B. Cardiomyopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
C. Regenerative Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
VIII. Therapeutics for Vascular Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
A. Atherosclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
B. Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
C. Aortopathy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
IX. Therapeutics for Cardiometabolic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 336
X. Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337
Abstract——Human induced pluripotent stem cells
(iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug dis-
covery. iPSCsallow for theproductionof limitless supply
ofpatient-specific somatic cells that enableadvancement
in cardiovascular precision medicine. Over the past
decade, researchers have developed protocols to
differentiate iPSCs to multiple cardiovascular lineages,
as well as to enhance the maturity and functionality of
these cells. Despite significant advances, drug therapy
and discovery for cardiovascular disease have lagged
behind other fields such as oncology. We speculate that
this paucity of drug discovery is due to a previous lack
of efficient, reproducible, and translational model
systems. Notably, existing drug discovery and testing
platforms rely on animal studies and clinical trials,
but investigations in animal models have inherent
limitations due to interspecies differences. Moreover,
clinical trials are inherently flawed by assuming that
all individuals with a disease will respond identically
to a therapy, ignoring the genetic and epigenomic
variations that define our individuality. With ever-
improving differentiation and phenotyping methods,
patient-specific iPSC-derived cardiovascular cells
allow unprecedented opportunities to discover new
drug targets and screen compounds for cardiovascular
disease. Imbued with the genetic information of an
individual, iPSCs will vastly improve our ability to test
drugs efficiently, as well as tailor and titrate drug
therapy for each patient.
I. Introduction
The groundbreaking discovery by Shinya Yamanaka
and colleagues that a set of four transcription factors
(Oct4/Sox2/c-Myc/Klf4) can induce reprogramming of
somatic cells to induced pluripotent stem cells (iPSCs)
has revolutionized the field of biomedical research,
providing an accessible, versatile, and adaptable plat-
form for precision medicine (Takahashi et al. 2007).
iPSCs generated from an individual can subsequently
be differentiated to a wide variety of functional somatic
cells, which can be used for cell or cell-free therapy for
regenerative medicine, in vitro patient-specific disease
modeling, drug testing, toxicity screening, and three-
dimensional organ/organoid construction (Shi et al.,
2017) (Fig. 1). In this review, we will examine in depth
the current state and the future applications of iPSC
technology to advance cardiovascular medicine and to
improve drug discovery methodologies.
Drug discovery requires years of preclinical research.
After a compound is synthesized, it must be rigorously
tested in preclinical studies (Dahlin et al., 2015).
Current models include primary cell culture and animal
models, the aim of which is to demonstrate proof of
principle that the drug under study is efficacious with
minimal side effects. Once this proof of principle is
established, the drug is eligible for clinical testing. The
Food and Drug Administration (FDA) uses properly
designed, double-blinded, multicenter trials to test
new drugs. As a result, after years of research and
testing, only a small fraction of drugs is introduced to
the market.
Although animal models and primary cell lines are
the most common methods for establishing efficacy and
safety in preclinical drug trials, there are significant
problems with each approach. Animal model systems
are inherently limited due to fundamental species
differences in physiology, reproducibility, ethical con-
cerns, and a poor correlation with human clinical trial
data (Begley and Ellis, 2012; Libby, 2015). For example,
mouse hearts beat at 500 beats per minute, whereas
ABBREVIATIONS: BMP, bonemorphogenetic protein; BMPR2, BMP receptor 2; CANTOS, Canakinumab Anti-Inflammatory Thrombosis Outcome
Study; CM, cardiomyocyte; cTnI, cardiac troponin I; DCM, dilated cardiomyopathy; DEX, dexamethasone; DIC, doxorubicin-induced cardiotoxicity; EC,
endothelial cell; ERK, extracellular signal-regulated kinase; ESC-CM, embryonic stem cell–derived CM; FDA, Food and Drug Administration; HCM,
hypertrophic cardiomyopathy; hERG, human ether-à-gogo–related gene; iPSC, induced pluripotent stem cell; iPSC-CM, iPSC-derived CM; LDL,
low-density lipoprotein; LMNA, lamin A/C; LVNC, left ventricular noncompaction; MESP1, mesoderm posterior protein 1; MHC, myosin heavy chain;
MLC, myosin light chain; NKX2-5, NK2 homeobox 5; NRVM, neonatal rat ventricular myocyte; PAH, pulmonary arterial hypertension; PCL, poly-
«-caprolacton; PCSK9, proprotein convertase subtilisin/kexin type 9; PDGF, platelet-derived growth factor; SGLT2, sodium-glucose transport protein 2;
ssTnI, slow skeletal troponin I; T2D, type 2 diabetes; T3, tri-iodothyronine; TGF, transforming growth factor; TKI, tyrosine kinase inhibitor; TNNT2,
troponin T2, cardiac type; TOP2B, topoisomerase II-b; VEGF, vascular endothelial growth factor; vSMC, vascular smooth muscle cell.
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human hearts normally range between 60 and 100 beats
per minute, limiting the utility of mice to study the
effects of anti-arrhythmic drugs. Animal model studies
are also difficult to reproduce (Liao and Zhang, 2008).
Primary cells extracted from human donors more di-
rectly reflect human physiology and pathology than
animal models, but the former are difficult to extract
and maintain. For example, human coronary endothe-
lial cells must be extracted from the coronary arteries of
human donors, a highly invasive procedure that yields
few cells that cannot be sufficiently expanded in culture.
As a result, coronary endothelial cells are often pooled,
eliminating any chance of ascertaining patient specific-
ity. Pools may also include cells isolated from both
healthy and diseased subjects, which canmuddle results.
Consequently, it is imperative that we generate low-cost,
quick procedures to discover test drugs, and that we
identify and tailor drugs designed specific to the individ-
ual patient (Dugger et al., 2018).
As an alternative to animal models and primary cells,
iPSC technology has triggered a paradigm shift in the
drug discovery and clinical trial landscapes. iPSCs
circumvent many of the problems associated with animal
and primary cell models and allow for the mass pro-
duction of disease- and patient-specific functional somatic
cells (Shi et al., 2017). In this study, we will discuss the
use of patient-specific iPSCs for generation of cardiovas-
cular cell types, the strategies for drug discovery using
iPSCs, and the use of iPSCs in precision cardiovascular
medicine.
II. Induced Pluripotent Stem Cells: A Platform
for Precision Medicine
The generation of cardiovascular cells derived from
patients allows individualized disease modeling, drug
screening, and drug testing. Currently, there are two
approaches to generate patient-specific pluripotent stem
cells from which cardiovascular cells can be derived:
1) generation of iPSCs by ectopic overexpression of
the Yamanaka transcription factors, and 2) somatic cell
nuclear transfer–derived embryonic stem cells using
enucleated human oocytes, a more technically challeng-
ing and ethically fraught procedure (Avior et al., 2016).
Genetically identical iPSCs match somatic cell nuclear
transfer–derived embryonic stem cells in their ability to
form terminally differentiated cells with appropriate
transcriptional, epigenetic, functional, and pharmaco-
logical features (Zhao et al., 2017b). As a result, iPSCs
have become the most popular cell source for generat-
ing patient-specific somatic cells.
Fig. 1. Applications of human iPSCs for precision medicine. Human iPSCs are differentiated to functional cardiovascular cells, providing an effective
platform for patient-specific disease modeling, cell-based therapy, cell-free therapy, drug testing and screening, and bioengineered tissue construction.
First, iPSC-derived cardiovascular cells can recapitulate patient-specific clinical phenotype in vitro, resulting in accurate genotype-to-phenotype
correlation. iPSC-derived cells allow elucidation of patient-specific disease mechanisms, enabling drug screening and toxicity testing that are unique to the
individual’s genetic and epigenetic makeup. iPSC-derived cells are also a source of cell-based therapy, allowing a patient’s own cells to be transplanted to
the damaged tissue. In addition, exosomes and microRNAs secreted from patient-specific iPSC-derived cells allow them to be used for cell-free therapeutic
purposes. Lastly, iPSC-derived cardiovascular cells can be engineered to create three-dimensional organoids or organ-like mimics of the heart or the blood
vessels for advanced disease modeling. Overall, the risk of tumorigenicity and poor cell survival rate remain as challenges to be addressed.
322 Paik et al.
iPSCs can give rise to a wide variety of cell types,
including cardiomyocytes (CMs) and vascular cells.
iPSC-derived CMs (iPSC-CMs) provide a platform to
effectively study patient- and disease-specific heart
disease conditions in vitro, includingLongQTsyndromes
(Itzhaki et al., 2011;Wang et al., 2014; Garg et al., 2018),
hypertrophic cardiomyopathy (Lan et al., 2013; Seeger
et al., 2019; Wu et al., 2019a), dilated cardiomyopathy
(Sun et al., 2012; Wu et al., 2015; Lee et al., 2019a),
Brugada Syndrome (Liang et al., 2016; Belbachir et al.,
2019), left ventricular noncompaction (Kodo et al., 2016),
LEOPARD syndrome (Carvajal-Vergara et al., 2010), and
arrhythmogenic right ventricular dysplasia (Akdis et al.,
2017; Te Riele et al., 2017). Recently, iPSCs have been
used to assess whether genetic variants in individual
patients are pathogenic or benign (Garg et al., 2018; Ma
et al., 2018) and have proven useful in patient-specific
drug screening and drug toxicity testing (Burridge et al.,
2016; Matsa et al., 2016; Sharma et al., 2017, 2018).
Similarly, human stem cell–derived vascular cell types
such as endothelial cells (ECs) and vascular smooth
muscle cells (vSMCs) are effective in modeling vascular
diseases such as pulmonary arterial hypertension (PAH)
(Gu et al., 2017) and for cell therapy in peripheral limb
ischemia (MacAskill et al., 2018). In addition, autologous
iPSC-based vaccine has arisen as a promising preventa-
tive and therapeutic strategy for combating various types
of cancers, as iPSCs have shown to share with tumor cells
a number of common antigens (Kooreman et al., 2018;
Ouyang et al., 2019; Wang et al., 2019).
III. Generation of Cardiac Muscle Cells from
Induced Pluripotent Stem Cells
Over the past decade, low-cost methods to derive
CMs from iPSCs with high efficiency (.90%) have
been developed (Lian et al., 2013; Burridge et al.,
2014), enabling mass production of human cardiac
muscle cells for various applications (Fig. 2). Despite
such remarkable progress, a number of major challenges
remain to be addressed. For example, iPSC-derived
cardiovascular cells generated with current methodol-
ogies exhibit a high level of unresolved functional and
transcriptomic heterogeneity, lacking the cellular matu-
ration required for adult cell-like phenotype. Notably,
the iPSC-CMs resemble fetal CMs in morphology, size,
electrophysiology, and contractile and metabolic func-
tions, necessitating the development of improved meth-
odologies to overcome these limitations (Chen et al.,
2016; Sayed et al., 2016).
A. Induced Pluripotent Stem Cell–Derived
Cardiomyocyte Differentiation
Cardiac differentiation is induced by themanipulation
of specific signaling pathways essential for cardiac de-
velopment and recapitulation of the embryonic cardiac
differentiationprocess: frompluripotent stage (OCT3/41,
NANOG1), to mesodermal lineage (T1, MIXL11), to
cardiac progenitor lineage (MESP11, NKX2.51), and
finally to relatively immature beating CMs (TNNT21,
MYH61) (Burridge et al., 2015; Paige et al., 2015).
Several key signaling pathways have been implicated
in directing stepwise differentiation, including the acti-
vin A, bone morphogenetic protein (BMP)4, fibroblast
growth factor 2, retinoic acid, and Wnt pathways.
In vitro cardiac differentiation protocols have dramat-
ically improved during the past decade (Burridge et al.,
2012). Initial differentiation protocols used embryoid body
formation, which was inefficient and labor-intensive
(Kehat et al., 2001; Mummery et al., 2012). Modern
protocols use chemically defined medium and small-
molecule compounds to induce CM differentiation from
amonolayer of iPSCs (Lian et al., 2012; Burridge et al.,
2014). First, the small-molecule glycogen synthase
kinase (GSK)-3b inhibitor CHIR99021 is used to pro-
mote differentiation of iPSCs to mesodermal lineage,
followed by a treatment with the canonical Wnt in-
hibitor compound IWR-1, IWR-4, XAV939, or C59 that
directs differentiation of these mesodermal cells to the
cardiac lineage. In these protocols, the use of serumhas
been eliminated and all medium components are fully
defined. These differentiation methods yield robustly
beating troponin T1 iPSC-CMs with a high efficiency at
manageable cost (Burridge et al., 2014).
B. Strategies to Generate Induced Pluripotent Stem
Cell–Derived Cardiomyocyte Subtypes
Because cardiovascular diseases affect distinct cham-
bers of the heart, it is necessary to develop methods to
generate chamber-specific iPSC-CM cellular subtypes.
For example, atrial CMs are required to assess the
mechanisms underlying atrial fibrillation, nodal CMs
for conduction disorders, and ventricular CMs for ven-
tricular tachycardia. Recent studies have described how
to modulate retinoic acid signaling during CM differen-
tiation to derive atrial- and ventricular-like CMs (Lee
et al., 2017a; Argenziano et al., 2018; Zhao et al., 2019),
as well as sinoatrial nodal pacemaker cell CMs (Protze
et al., 2017). These chamber-specific CMs are shown to be
functionally distinct, as the calcium-handling properties
of the derived atrial iPSC-CMs are different from those of
ventricular or nodal iPSC-CMs (Argenziano et al., 2018).
Generation of a double-reporter iPSC line that enables
isolation of cells from first and second heart field can also
help in distinguishing atrial and ventricular iPSC-CMs,
epicardial cells, and ECs (Zhang et al., 2019b). Tissue
engineering techniques enable creation of electrophysio-
logically distinct atrial and ventricular 3D microtissues,
which have been shown to exhibit chamber-specific gene
expression anddrug responses to seratonin and ranolazine
(Zhao et al., 2019). Furthermore, advances in single-cell
sequencing have greatly aided our understanding of the
iPSC-CM differentiation process and the transcriptional
regulations that govern iPSC-CM subtype specification
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(Churko et al., 2018; Friedman et al., 2018). Lastly, efforts
have been made to derive specialized populations of non-
myocyte cells of the heart, such as cardiac progenitor cells
(Lalit et al., 2016), epicardial cells (Bao et al., 2016; Zhao
et al., 2017a), cardiac fibroblasts (Zhang et al., 2019a), and
valve interstitial-like cells (Nachlas et al., 2018), from iPSCs.
C. Challenges in Induced Pluripotent Stem
Cell–Derived Cardiomyocyte Maturation
It is essential that iPSC-CMs recapitulate an adult
CM phenotype for bona fide disease modeling, drug
screening, and toxicity testing. However, iPSC-CMs
differ from adult CMs in theirmorphology, contractility,
metabolism, electrophysiology, and response to calcium
and b-adrenergic stimulation. To date, researchers have
attempted hormone/steroid–, culture substrate–, genetic-,
three-dimensional tissue engineering–, and mechanical
and electrical–based methods to mature iPSC-CMs, yet
no single method has been accepted as the gold standard
(Veerman et al., 2015; Bedada et al., 2016). Below we
describe the major phenotypic differences between iPSC-
CMs and adult CMs and discuss current methods avail-
able to address the immaturity of iPSC-CMs.
1. Cellular Morphology. The iPSC-CMs generated
using standard protocols display round or polygonal
cellular morphology with sarcomeric disorganization,
whereasmature adult CMs are rod-shaped and elongated
with an aspect ratio of 5:1 to 9:1 and an anisotropic
distribution of myofilaments (Gerdes et al., 1992; Ribeiro
et al., 2015a). The rod-shaped morphology promotes
the longitudinal alignment that mature CMs need to
facilitate rapid electrical conduction and efficient muscle
contraction (Kleber and Saffitz, 2014; Vreeker et al., 2014).
By contrast, iPSC-CMs are highly disorganized and lack
a dominant axis of myofibril alignment (Feaster et al.,
2015). iPSC-CMs also exhibit a smaller surface area, as
measured bymembrane capacitance (Hwang et al., 2015).
Differences in organelle morphology and distributions
between iPSC-CMs and adult CMs are also evident. Fetal
and adult CMs have different numbers of nuclei, and
ploidy perCM increaseswith cellularmaturation (Mollova
et al., 2013). iPSC-CMs are mostly mononucleated, re-
sembling fetal CMs (Snir et al., 2003). iPSC-CMs also lack
developed t-tubule networks necessary for efficient
contractile function in adult CMs (Ibrahim et al., 2011).
2. Contractility. iPSC-CMs differ from adult CMs in
contractile and electrophysiological functions. Tulloch
et al. (2011) reported that the peak twitch tension of
human embryonic stem cell–derived CMs (ESC-CMs) in
collagen constructs was measured at ;0.08 mN/mm2,
nearly 550-fold less than that of adult human myocar-
dium. Using dynamic traction force microscopy to mea-
sure lateral force generation, Kita-Matsuo et al. (2009)
reported individual cells plated on gelatin-functionalized
Fig. 2. Generation of cardiovascular cells from iPSCs. Somatic cells such as dermal fibroblasts or peripheral blood mononuclear cells isolated from
individual patients can be reprogrammed to iPSCs via viral delivery of the four Yamanaka transcription factors (OCT41, SOX21). Most commonly, iPSCs are
pushed to precardiac mesodermal lineage (KDR1, MESP11) via GSK-3b inhibition, and then differentiated to cardiac progenitor cells (ISL11, NKX2-51) by
canonical Wnt signaling inhibition. Functional cardiomyocytes (TNNT21, ACTN21), smooth muscle cells (CNN11, MYH111), or endothelial cells (CDH51,
PECAM11) are generated by treatment with unique sets of growth factors and small molecules. Epicardial cells (WT11, TBX181) can also be generated from
cardiac progenitor cells, which can then be differentiated to cardiac fibroblasts (POSTN1, DDR21). Generation of endocardial cells (NFATC11), either from
cardiac progenitors or endothelial progenitors, is still under development. Recently, methods to generate atrial, ventricular, and nodal cardiomyocytes have
been described. To date it is not clear whether specialized subtypes of endothelial cells or stromal cells can be made from iPSCs.
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surfaces of polyacrylamide casts contracted with an
average total force of 144 nN, whereas neonatal rat
ventricularmyocytes (NRVMs) contracted with 222 nN
total force under identical conditions. Differences in
total force are attributed to the differences in gener-
ated traction, as the NRVMs displayed a higher aspect
ratio (length of the long axis divided by the length of
the short axis) than ESC-CMs. The ratio of axial to
total force was comparable between NRVMs and ESC-
CMs, indicating that variations inmorphologic alignment
did not contribute to polarization of force generation.
More recently, cardiac tissue formed with early-stage
iPSC-CMs was found to display adult-like contractility
and a positive force–frequency relationship, suggesting
that it may be necessary to combine three-dimensional
tissue construction of iPSC-CMs with supporting cell
types to achieve full contractile function (Mannhardt
et al., 2016; Ronaldson-Bouchard et al., 2018).
3. Sarcomeric Protein Isoforms. Isoform switching
is a common developmental phenomenon in many cell
types, including CMs. These switches in the expression
of functional sarcomeric protein isoforms serve as useful
markers in determining the maturity level of CMs. In
the mammalian heart, a stoichiometric switch in the
expression level of cardiac troponin I (cTnI) isoforms
occurs during CM maturation. In the fetal heart, slow
skeletal troponin I (ssTnI) expression predominates
over cTnI expression, whereas in the adult heart cTnI
expression rises and ssTnI levels decrease (Bedada
et al., 2014). Similarly, ratios of myosin heavy chain
(MHC) and myosin light chain (MLC) protein isoforms
differ between fetal and adult CMs. In the fetal heart
b-MHC and MLC2a expression dominates, whereas in
the adult heart a-MHC and MLC2v expressions take
over (Reiser et al., 2001). Finally, fetal CMs predomi-
nantly express the N2BA isoform of titin, a sarcomeric
protein that anchors Z-discs to the M-lines of the sarco-
mere, whereas adult CMs primarily express the N2B
isoform of titin (Opitz et al., 2004).
iPSC-CMs were shown to express ssTnI even after
long-term culture, indicating the relative immaturity of
the cells (Bedada et al., 2014). Ascertaining accurate
ratios of b-MHC/a-MHC and MLC2a/MLC2v in iPSC-
CMs is complicated due to the heterogeneity of atrial
and ventricular CMs present in iPSC-CMs (Ivashchenko
et al., 2013; Lundy et al., 2013). ESC-CMs were shown to
express the N2BA isoform of titin, found primarily in
fetal CMs (Neagoe et al., 2002; Opitz et al., 2004). Taken
together, these data suggest the cTnI:ssTnI ratio and the
titin isoform N2B:N2BA ratio are the preferred genetic
markers to assess the maturation of iPSC-CMs.
4. Mitochondrial Function and Metabolism.
Mitochondria are highly abundant in the heart, com-
prising up to 23% of human, 28% of rat, and 32% of
mouse myocardium (Schaper et al., 1985). In humans,
most adult CMmitochondria are rod-shaped and aligned
evenly with sarcomeres (Robertson et al., 2013). Cellular
factors controlling mitochondria, including fusion fac-
tors Mfn1, Mfn2, and Opa1 and fission factor Drp1, are
abundantly expressed in adult CMs (Chung et al.,
2007). In comparison, ESC-CMs have thinner and
fewer elongated mitochondria (Hattori et al., 2010),
often clustered adjacent to the nucleus with dimin-
ished expression of mitochondrial dynamics proteins
(Gherghiceanu et al., 2011).
Glycolysis is a major energy source for CMs during
early cardiac development. With CM maturation and
differentiation, mitochondrial oxidation, primarily in
the form of fatty acid b-oxidation and glucose oxidation,
becomes the major energy source for the adult heart.
Interestingly, in certain pathologic conditions such as
hypertrophic cardiomyopathy, adult cardiac metabo-
lism switches back to a more fetal phenotype with less
b-oxidation and more glycolysis (Lopaschuk and
Jaswal, 2010). Consistent with their immature fetal-like
phenotypes, ESC-CMs are predominantly glycolytic with
the presence of oxidativemetabolismmainly in the formof
lactate oxidation (Rana et al., 2012). The transcriptome
and metabolism of the ESC-CMs resemble those of the
fetal CMs more than the adult CMs (Gaspar et al., 2014).
Oxidative phosphorylation genes in fact are expressed in
ESC-CMs at even lower levels than in fetal CMs (Ojamaa
et al., 1996).
D. Approaches to Enhance Induced Pluripotent Stem
Cell–Derived Cardiomyocyte Maturation
Attempts to improve the maturation of iPSC-CMs
include prolonged culture duration, treatment with tri-
iodothyronine (T3) or dexamethasone (DEX), culture
substrate variations, three-dimensional tissue engineer-
ing, electrical stimulation, and genetic approaches (Yang
et al., 2014; Bedada et al., 2016; Tu et al., 2018). Initial
efforts included prolonging the duration of iPSC-CM
culture. For example, iPSC-CMs cultured for 80 to
120 days displayed greater cell size and elongation,
with increased density and alignment of myofibrils
(Lundy et al., 2013). Long-term cultured iPSC-CMs
exhibited faster calcium-transient kinetics, enhanced con-
tractility, and adrenergic responsiveness to isoproterenol.
PKA (protein kinase A)- and proteasome-dependent sig-
naling axis has been implicated to modulate mitochondrial
respiratory chain proteins and enhance the metabolic
output of long-term cultured iPSC-CMs, resulting in the
increased contractility (Ebert et al., 2019). However,
sarcomeric organization remains heterogeneous and
does not resemble that of adult CMs, indicating a re-
quirement of additional stimulus to achieve the full
maturation.
Treatment of T3 on murine ESC-CMs was shown to
upregulate NKX2-5, MLC-2v, a-, and b-MHC expression
and to enhance the electrophysiological properties of
the cells, increasing maximal upstroke velocity and
peak amplitude of caffeine-induced calcium transients
(Lee et al., 2010). Similarly, iPSC-CM differentiation in
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a medium containing T3 was shown to promote molec-
ular, morphologic, and functional maturation of the
cells, with a 2-fold increase in contraction stress of the
cells (Ribeiro et al., 2015b). Microarray analysis showed
that iPSC-CMs cultured in presence of T3 resembled
second-trimester human fetal hearts, whereas control
iPSC-CMs resembled first-trimester human fetal hearts
(van den Berg et al., 2015). This indicates a role of T3 in the
maturationof iPSC-CMs.However, itwasalso reported that
T3 treatment did not affect the cTnI protein isoform ratio,
a genetic marker for CM maturation (Bedada et al., 2014).
Synthetic glucocorticoid DEX has been shown to
induce binucleation and inhibit proliferation of CMs in
P4 and P7 neonatal rats by epigenetic suppression of
cyclinD2 (Gay et al., 2015, 2016). Inhibition of globalDNA
methylation by 5-azacytidine blocked DEX-mediated
downregulation of cyclin D2, suggesting that DEX acts
on glucocorticoid receptors to inhibit proliferation and
promote cardiac differentiation. Binucleation and sup-
pressed proliferative activity of CMs indicate terminal
differentiation and maturation of the cells.
The dynamic cellular environment of the heart tissue
is not recapitulated in a two-dimensional monolayer
culture of cells. To address this, several studies have
used culture substrates with altered stiffness and spe-
cific patternings that more closely resemble those of the
native tissue. Feaster et al. (2015) cultured single iPSC-
CMs on a 0.4- to 0.8-mm–thick mattress of undiluted
Matrigel for 5 to 7 days that yielded rod-shaped iPSC-
CMs with increased sarcomere length when compared
with traditional culture substrate of ,0.1-mm–thick,
dilutedMatrigel. Contractility of themattress iPSC-CMs
was comparable to that of rabbit ventricular CMs and of
late-stage iPSC-CMs after 80 to 120 days in culture. In
addition, the mattress iPSC-CMs responded to positive
and negative inotropic agents, such asmyofilament Ca12
sensitizer EMD57033 and Ca-channel antagonist verap-
amil in a concentration-dependentmanner. By screening
a library of polymers comprised of poly-«-caprolacton
(PCL), polyethylene glycol, and carboxylated PCL, Chun
et al. (2015) found that culturing iPSC-CMs on 4% poly-
ethylene glycol–96% PCL resulted in high contractility
and mitochondrial function of the cells, as well as more
mature gene expression patterns, including induction of
MLC2v and isoform switching from ssTnI to the post-
natal form cTnI.
Genetic approaches have also been promising. To
mimic the switch of TnI isoforms during CMmaturation
of developing heart, Bedada et al. performed exogenous
adenoviral-mediated gene transfer of human cTnI to
iPSC-CMs, which successfully altered the cTnI:ssTnI
isoform ratio (Bedada et al., 2014). Histone H3 acetyla-
tion chemically induced in iPSC-CMs by treatment with
the histone deacetylase inhibitor trichostatin A in-
creased cardiac gene expression and improved responses
to potassium ion channel inhibitors. A combinatorial set of
transcription factors known to induce cardiac hypertrophy
(Heineke and Molkentin, 2006) such as GATA4, nu-
clear factor kB (NF-kB), myocyte enhancer factor-2,
serum response factor, and EGR1 should be considered
as promising targets of genetic approaches to enhance
iPSC-CM maturation.
Approaches to create three-dimensional cardiac tis-
sue (Eder et al., 2016; Mathur et al., 2016) and to
stimulate the cells with mechanical and electrical
stimuli (Chan et al., 2013; Ruan et al., 2016) have also
been reported. Cardiac tissue made with iPSC-CMs in
fibrin hydrogel was subjected to stretch and auxotonic
contractions for 4 weeks, resulting in maturation of
molecular, structural, and metabolic properties of
iPSC-CMs (Ronaldson-Bouchard et al., 2018). Com-
bined stimuli promote contractility, calcium-handling
protein expression, and passive mechanics of engineered
cardiac tissue. Limitations of these techniques include
the inability to scale up for high-throughput screening of
multiple samples in parallel, which is currently being
addressed via novel approaches such as the cardiopatch
platform (Shadrin et al., 2017).
IV. Generation of Vascular Cells from Human
Induced Pluripotent Stem Cells
A. Endothelial and Smooth Muscle
Cell Differentiation
To generate vascular cell types such as ECs and
vSMCs, iPSCs are first differentiated to mesodermal
progenitors, then induced to vascular lineages by treat-
ment with vascular endothelial growth factor (VEGF)-A
to induce ECs (Patsch et al., 2015; Sayed et al., 2015;
Williams and Wu, 2019) with platelet-derived growth
factor (PDGF)-BB, activin A, and transforming growth
factor (TGF)-b1 to induce vSMCs (Dash et al., 2015).
Similar to vascular development in vivo, canonical Wnt
activation followed by Bone Morphogenetic Protein 4
(BMP4) signaling led to formation of mesodermal pro-
genitors most suitable for generation of ECs and vSMCs.
The efficiency of pluripotent stem cells to EC differenti-
ation is suboptimal, ranging from 10% to 35% (Patsch
et al., 2015; Paik et al., 2018). Consequently, to isolate
pure iPSC-EC populations, differentiated cells are
subjected to magnetic-associated cell sorting with
bead-conjugated CD144 antibody on the final day of
differentiation. Sorted iPSC-ECs exhibit bona fide EC
characteristics, including tube-like network forma-
tion, upregulation of surface adhesion molecules in
response to proinflammatory cytokines, nitric oxide
release, and acetylated low-density lipoprotein (LDL)
uptake. Single-cell RNA sequencing of iPSC-ECs
identified four subpopulations of iPSC-ECs, marked
by enriched expression of CLDN5, APLNR, GJA5, and
ESM1 (Paik et al., 2018). Notably, GJA51 iPSC-ECs
represented arterial-like cells, whereas ESM11 iPSC-
ECs represented cells in activated, proangiogenic
state. Approaches to enrich for iPSC-ECs with arterial,
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venous, and lymphatic phenotype are under develop-
ment (D’Souza et al., 2018; Uenishi et al., 2018). Over-
expression of SIRT1 by lentiviral delivery has been
reported to prolong iPSC-EC morphology and pro-
liferative capacity by delaying early cell senescence
(Jiang et al., 2015).
iPSC-vSMC differentiation relies primarily on treat-
ment of growth factors PDGF-BB and TGF-b1 to yield
a putatively pure populations of CD140b1 vSMCs with-
out additional cell-sorting steps (Wanjare et al., 2013;
Patsch et al., 2015). Different plate-coating materials
and growth factor treatment have been reported to
prolong culturing of iPSC-vSMCs under either synthetic
or contractile conditions (Patsch et al., 2015). Cheung
et al. 2012 delineated chemically defined protocols to
generate origin-specific iPSC-vSMCs from intermediate
lineages of neuroectoderm, lateral plate mesoderm, and
paraxial mesoderm, which also resulted in highly pure
populations of vSMCs with robust expression of early
SMCmarkersACTA2, TAGLN, andCNN1and late SMC
markers SMTN andMYH11. The resulting iPSC-vSMCs
exhibited SMC functionalities such as cell migration,
extracellular matrix interaction, and actin cytoskeleton
organization. Generating iPSC-vSMCs in alginate hydro-
gel microtubes has recently been reported as a scalable
method for producing contractile and less proliferative
vSMCs with increased expression of ECM genes (Lin
et al., 2019). The purity of iPSC-vSMCs obtained with
currently availablemethodologies however remains ques-
tionable, given the imperfect differentiation efficiencies of
other cardiovascular lineages in the absence of cell type-
specific purification steps. Existing iPSC-vSMC protocols
can thus benefit from additional refinements to derive
the cells with higher purity, which will enable more
accurate discerning of the molecular signatures of vas-
cular diseases without the noise of unwanted cell types.
B. Applications of Induced Pluripotent Stem
Cell–Derived Vascular Cells
Patient-specific iPSC-ECs can be used to model the
clinical phenotypes of vascular diseases in vitro.
iPSC-ECs from idiopathic and familial PAH patients
exhibited endothelial dysfunction similarly to native
pulmonary arterial ECs isolated from the same patients
(Sa et al., 2017). iPSC-ECs derived from familial PAH
patients displayed reduced adhesion, survival,migration,
and angiogenesis in comparison with healthy counter-
parts (Gu et al., 2017). Disease phenotypes of familial
PAH patients whose BMP receptor 2 (BMPR2) mutation
impaired cell adhesion and survival of ECs were reca-
pitulated in the iPSC-ECs. Specifically, familial PAH
iPSC-ECs carrying the BMPR2mutation were not able
to activate noncanonical pP38 signaling pathway in
response to BMP4. CRISPR/Cas9 gene editing corrected
the pathogenic BMPR2 mutation in the patient iPSC
lines and rescued the pathologic phenotype. Calcific
aortic valve disease patients’ iPSC-ECs were used to
describe the epigenetic mechanism of NOTCH1 haploin-
sufficiency in activation of latent pro-osteogenic and
inflammatory gene networks (Theodoris et al., 2015).
iPSC-ECs can also serve as an essential component of
bioengineered organoids or three-dimensional organ
structures (Nakayama et al., 2015; Kim et al., 2016).
In addition, iPSC-ECs have shown promise as a
source for cell therapy for ischemic disease conditions
(Rufaihah et al., 2011; MacAskill et al., 2018), although
poor survival and engraftment still remain major
obstacles. A mixture of extracellular matrix compo-
nents was used to enhance post-transplantation via-
bility of iPSC-ECs within three-dimensional scaffolds,
suggesting optimized microenvironments can improve
survival and engraftment of iPSC-ECs in hypoxic con-
ditions (Hou et al., 2016; Lee et al., 2017b). Exosomes and
microRNAs secreted from iPSC-derived cardiovascular
cells bear potential for cell-free therapeutic strategies
(Jung et al., 2017). In addition, iPSC-ECs can serve as
a toxicity-screening platform in assessing endothelial
dysfunction triggered by nicotine and e-cigarette products
(Lee et al., 2019b) as well as environmental toxins (Tang
et al., 2017).
Similarly to iPSC-ECs, iPSC-vSMCs have been used
effectively in investigating disease mechanisms of vSMC
dysfunction (Maguire et al., 2017). For example, Marfan
syndrome is a heritable connective tissue disorder char-
acterized bymutations in the FBN1 gene andmanifested
in development of thoracic aortic aneurysm (Granata
et al., 2017). iPSC-vSMCs from Marfan Syndrome
patients recapitulated in vitro the pathologic presen-
tation of the disease, such as abnormal extracellular
matrix degradation and aberrant TGF-b signaling
and apoptosis of vSMCs. Such abnormalities were
rescued by gene editing of FBN1 mutation by CRISPR/
Cas9, which identified the role of p38 mitogen-activated
protein kinase and KLF4 in regulation of vSMC pro-
liferation and apoptosis that leads to the pathology of
Marfan syndrome (Granata et al., 2017). Likewise, iPSC-
vSMCs from supravalvular aortic stenosis andWilliams–
Beuren syndrome patients with premature termination
of ELN gene revealed that small GTPase RhoA signaling
and extracellular signal-regulated kinase (ERK)1/2 ac-
tivity regulate hyperproliferation of iPSC-vSMCs, re-
sponsible for pathology of the disease (Ge et al., 2012).
iPSC-ECs and iPSC-vSMCs together have shown to be
a critical source of three-dimensional tissue-engineered
blood vessels for regenerative medicine therapeutic
applications and for diseasemodeling of vascular diseases
(Dash et al., 2016; Gui et al., 2016;Wimmer et al., 2019a).
V. Strategies for Induced Pluripotent Stem
Cell–Based Drug Discovery and Testing
A. Methods for Cardiovascular Drug Screening
1. Tissue-Specific Response. iPSCs provide the po-
tential to rapidly screen thousands of novel drug
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compounds, personalize medical therapy, and repurpose
medications for cardiovascular disease, as iPSC-derived
cardiovascular cells can be used to screen drug libraries
in a high throughput manner (Del Álamo et al., 2016;
Sharma et al., 2018). For example, iPSC-CMs can test
for adverse response to potential drug targets with
next-generation sequencing and proteomics analysis. In
a recent study, iPSC-CMswere stimulated with hydrogen
peroxide to mimic ischemic injury in vitro, and short
hairpin RNA–mediated gene silencing was used to vali-
date a candidate target mitogen-activated protein kinase
kinase kinase kinase-4 (MAP4K4) (Fiedler et al., 2019).
Using a chemical screen, a novel small-molecule com-
pound was found to promote survival of iPSC-CMs af-
ter ischemic injury, showing the potential in iPSC-derived
cells to perform a tissue-specific high-throughput screen-
ing of drug compounds. In addition, cellular phenotyping,
including calcium studies, multiple electrode arrays, and
atomic force microscopy, is used to further define the
patient-specific response to the candidate drug.
2. Organ-on-a-Chip for Optimizing Therapy and
Screening Side Effects. iPSCs can be differentiated into
various tissue types and tested for side effects using
biochemical and cellular phenotyping for transcriptome
and proteomic profiles to predict adverse drug reac-
tions. The use of organ-on-a-chip or organoid models
will facilitate the detection of unwanted side effects,
thus ensuring drugs used in clinical trials would cause
minimal morbidity and mortality. iPSC-derived car-
diovascular tissues can screen for effects on multiple
tissue simultaneously and assess crosstalks among dif-
ferent cell types in response to a drug (Tzatzalos et al.,
2016; Liu et al., 2018; Wnorowski et al., 2019). Taken
together, the use of organ-on-a-chip models will help
determine the global efficacy and safety profile for novel
compounds, eliminating the need to conduct testing in
primary cell culture and animal models that are consid-
ered unethical or rarely translatable clinically.
The human ether-à-go-go–related gene (hERG) encodes
the inward rectifying voltage-gated potassium channel in
the heart, involved in cardiac repolarization (Warmke
and Ganetzky, 1994). hERG testing of pluripotent stem
cell–derived CMs has the potential to identify drugs that
cause QT prolongation (Curran et al., 1995; Sanguinetti
et al., 1995; Sanguinetti and Tristani-Firouzi, 2006).
hERG tests are an example of harnessing the power of
pluripotent stem cell platforms to identify potentially fatal
side effects. Although iPSC platforms have the capacity to
detect cardiotoxicity, routine testing with iPSC platforms
has not yet been fully integrated into the drug-screening
algorithm of pharmaceutical industries, although multi-
site testings are now underway (Blinova et al., 2018).
3. Precision Therapies Using Induced Pluripotent
Stem Cells. Meta-analysis of different drugs in the same
classmay also reveal that all individuals respond to drugs
in the same class, a phenomenon known as a class
effect. In the clinic, however, some drugs are more
effective than others and have a better side effect
profile. All patients are unique, and their individual
responses to a drug will vary.
The cause of the variation may be due to the differ-
ences in the genetic code caused by single-nucleotide
polymorphisms. The goal of precision therapy is to
deliver the right medicine at the right time to the right
individual. In the past, cohorts were selected based on
demographic, biometrics, and cardiovascular risk fac-
tors or disease state. More recently, trials such as the
Justification for the Use of Statins in Prevention: an
InterventionTrialEvaluatingRosuvastatin (Ridker et al.,
2008) and the Canakinumab Anti-Inflammatory Throm-
bosis Outcome Study (CANTOS) (Ridker et al., 2017)
have used biomarkers to aid in patient recruitment.
The personalized tailoring of medical therapy depends
on each patient’s unique genetic makeups, lifestyle,
and environmental exposures.
iPSCs offer a window into an individual’s unique re-
sponse to a drug. The iPSCs retain the individual’s genetic
information, and when differentiated into the appropriate
tissue subtypes, can reveal unique transcriptomic, metab-
olomics, and proteomic profiles (Matsa et al., 2016; Lam et
al., 2019). Armed with these novel biomarkers, a clinician
can tailor therapy to any individual patient to maximize
beneficial effects and minimize side effects.
4. Predicting Responders and Nonresponders to
Avoid Trial and Error. Over the past century, we have
witnessed astonishing progress in the treatment of car-
diovascular disease. Using animal models and primary
cell cultures, mechanisms of cardiovascular disease have
been uncovered and drug therapies for atherosclerosis
rigorously tested in clinical trials. With the development
of statins, mortality and the incidence of cardiovascular
events have declined significantly. Following the mantra
of lowering cholesterol levels, amultitude of clinical trials,
including the Pravastatin or Atorvastatin Evaluation and
Infection Therapy—Thrombolysis in Myocardial Infarc-
tion 22, a randomized trial of cholesterol lowering in 4444
patients with coronary heart disease, the Scandinavian
Simvastatin Survival Study (4S), and Myocardial Ische-
mia Reduction with Aggressive Cholesterol Lowering,
have demonstrated the tremendous power of statins to
alter the trajectory of atherosclerotic disease (Schwartz
et al., 2001; Cannon et al., 2004; Pedersen et al., 2004).
The current standard of care for primary prevention is
to place a patient who has moderate or high risk on
a statin, and all patients should be on a statin for
secondary prevention (Stone et al., 2014). In the clinic,
however, we find patients who do not respond as well
to statin therapy, and many patients have reported
adverse side effects.
Although statin therapy is essential for preventing
cardiovascular deaths and improving survival, the
implementation is difficult and often frustrating for
both patients and clinicians. Similarly, patients with
atrial fibrillation are prescribed rhythm or rate control
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strategies based on patients’ symptoms and preferen-
ces. Using an iterative process, clinicians and patients
work together to find a drugwith the best risk-to-benefit
ratio. More broadly, iPSCs could identify subpopula-
tions that would respond to therapy and experience the
benefits of a drug while minimizing the adverse effects.
Using iPSC-derived skeletalmyoblasts, high-throughput
assay for screening statin-induced myopathy was devel-
oped to test for mitochondrial integrity and cytoplasmic
integrity (Klaren and Rusyn, 2018). With lowered cost
of the assay and increased accessibility of iPSC-derived
cells, such platform will be critical in distinguishing
responders versus nonresponders in vitro.
5. Optimizing Clinical Trials. Patients who meet
clinical trial entrance criteria should respond appropri-
ately to therapy. The dilemma is that many trials, despite
being adequately powered, fail to show improvement or
even demonstrate adverse events in the enrolled patients.
Clinical trials are designed with entrance and exclusion
criteria to select responders to treatment and minimize
adverse side effects. For example, theCardiacArrhythmia
Suppression Trial (CAST) was designed to show the
efficacy of antiarrhythmic drugs in suppressing ventricu-
lar arrhythmias in ischemic cardiomyopathy (Echt et al.,
1991). However, part of the outcomewas an unexpected
increase in death due to arrhythmic death and shock.
Because of their unique advantages, iPSCs could be
used to predict hazard and further enhance exclusion
criteria to avoid adverse effects (Kopljar et al., 2018;
Wu et al., 2019b).
There already exist several examples of iPSC-CMs in
modeling drug-induced toxicity with the potential to
guide clinical management. Tyrosine kinase inhibitors
(TKIs) are a powerful family of cancer therapies, but,
unfortunately, some patients exhibit susceptibility to
cardiotoxicity and arrhythmias from TKIs. Sharma
et al. (2017, 2018) eloquently used human iPSC-CMs
to screen in vitro for specific TKIs that cause cardiotox-
icity and discovered thatVEGF/PDGF receptor inhibition
was important for causing cardiotoxicity. Pharmaceutical
companies can likewise benefit frompreclinical screening
approaches with iPSC-CMs to identify compounds that
cause cardiotoxicity and morbidity and to reduce time
and funding required for clinical trials (Strauss and
Blinova, 2017; Fermini et al., 2018).
The cardiotoxic effects of a drug may be patient-
specific due to inherited factors. In another study,
Burridge et al. (2016) used patient-specific iPSC-CMs
to predict whether an individual would develop cardio-
toxicity to anthracyclines. As such, the use of iPSC-CMs
can guide patient-specific treatment and identify drugs
are effective in some individuals and harmful in others,
with the potential to rescue drugs that were previously
discarded as unsafe due to malignant side effects in
a specific cohort of individuals. Greater detail on cancer
therapy–induced cardiotoxicity is discussed inSectionVI
of this review.
The cost of developing a drug is approximately $ 2.6
billion, with over 80% of the funds spent in the clinical
trials phase of drug development and with approxi-
mately seven of eight drugs failing to make it into the
clinic (DiMasi et al., 2016). iPSC-based drug screening
boasts the power to identify drug toxicities, such as
anti-arrhythmics that paradoxically have caused more
cardiovascular death. By quickly failing at the pre-
clinical stage, a pharmaceutical company can avert
a clinical trial and save billions of dollars that can be
repurposed.
Traditional biomarkers require the use of biomet-
rics, serum proteins, and imaging. In this omics era
of today, future trial designs may incorporate indi-
vidual profiles from genetics, transcriptomics, metab-
olomics, and proteomics. Using this highly tailored
approach, a drug will be more efficacious in recep-
tive populations. Clinical trials that may have shown
a signal for a positive response using traditional
selection criteria would be more likely to be clinically
significant.
B. Strategies for Induced Pluripotent Stem Cell–Based
Drug Discovery
Drug screening and testing using patient-specific
iPSCs enable the realization of “clinical trial in a dish”
to reduce the exorbitant cost and inefficiency of the
current drug development pipeline in the United
States and other countries. The use of disease- and
patient-specific iPSCs in drug screening and test-
ing will also reduce trial and error and optimize patient
selection for clinical trials, by accurately predicting
responders versus nonresponders with greater accu-
racy (Fig. 3).
1. In Silico Prediction for Candidate Drugs. In silico
analysis predicts compounds binding to drug target
receptors. The structure of a receptor must be known
to allow a known ligand to facilitate the modeling of
binding with the use of a compound library. Designed
algorithms can predict binding to putative ligands,
which must be subsequently validated in vitro or
in vivo (Lionta et al., 2014; Kernik et al., 2019). Use
of iPSCs can facilitate in silico drug discovery by
providing a platform to validate novel drugs in a high
throughput manner. Moreover, iPSC disease modeling
may uncover novel targets. Thus, iPSCs not only can
validate drugs but also find new targets for in silico
drug discovery.
2. Repurposing Drugs for Cardiovascular Disease.
An existing drug may be repurposed for a new indica-
tion. For example, colchicine is an anti-inflammatory
drug for gout, which found off-label use in other inflam-
matory conditions such as pericarditis and postopera-
tive pericarditis syndrome (Imazio et al., 2005, 2013).
Existing drugs can be repurposed for other clinical
indications, with the use of iPSCs to facilitate screen-
ing existing FDA-approved drugs for cardiovascular
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indications, helping to reduce or eliminate the costly
preclinical screening normally needed to ensure safety
and efficacy.
3. Screening Novel Compounds. Drug screening can
involve creating new compounds from scratch or using
existing molecules to design novel compounds with
improved efficacy or side effect profile. Rational drug
design can be used to synthesize a multitude of
compound (Drews, 2000). The efficacy and side effect
profile of each compound, however, must be validated
in a biologic model before expensive and lengthy
clinical trials. Dronedarone is an example of premodify-
ing a drug structure in an attempt to minimize toxicity
and to retain its pharmacological benefit. The result,
however, was a less potent antiarrhythmic drug with
more adverse effects than the original (Connolly et al.,
2011). The use of iPSCs therefore can allow screening
of candidate drugs for toxicity and adverse effects
before the initiation of clinical trials to save time
and cost.
C. Challenges of Implementing Pluripotent Stem Cell
Platforms in Industry
Despite the many advantages for drug discovery,
pluripotent stem cells have not yet gained traction in
the pharmaceutical industry. ESC-based strategies face
a significant stigma with ethical concerns. The use of
iPSCs can avoid this issue and has many advantages
over ESCs. iPSCs retain the genetic information of an
individual and provide a unique opportunity to advance
personalized medicine. In regenerative therapy, the use
of iPSCs may eliminate the need for immunosuppres-
sion, which is needed for the case of ESCs. Genome
editing can further augment the power of iPSCs to
correct mutations causative of the disease. Although
gene therapy is not yet feasible, gene editing will
uncover novel mechanisms of disease and targets for
small-molecule therapies, which when combined with
iPSCs will advance the development of novel personal
therapies.
However, iPSC-based platforms are not yet high
throughput, remain expensive, and require storage
for the delivery of regenerative therapies in a timely
manner. The cost of drug discovery with iPSC platforms
could be enormous, as each personwould require a blood
sample or tissue sample to be reprogrammed and sub-
sequently differentiated. This individualized approach
inevitably takes time because the reprogramming and
differentiating process can take up to 6 months for each
individual, not counting the time needed for recruiting
patients into the study. Making the drug discovery
process high throughput may thus prove more difficult
than expected, as disease modeling likely will add
considerable complexity to the drug-screening process,
and titrating for each individual may require multiple
iterations.
Solomon et al. (2015) and Lee et al. (2018) have
devised a strategy to partially circumvent the chal-
lenges of drug screening and regenerative therapy with
iPSCs by generating banks of cell lines, in which a
diverse set of iPSC lines from healthy individuals with
varying combinations of commonly present HLA alleles
is banked. The iPSCs with common but not identical
HLA profile will be differentiated and may be used for
regenerative therapeutic solution. The resulting iPSC-
derived cellswill nonetheless require immunosuppression,
Fig. 3. Drug screening and testing using patient-specific iPSCs. Patient-specific iPSCs provide a platform for personalized drug screening and testing.
iPSCs generated from individual patients are differentiated into cardiovascular cells of interest and subjected to drug treatment in vitro. High-
throughput methods allow functional characterization of the cells during or after drug treatment, from which responders vs. nonresponders and the
side effects of the drug are identified. This information allows informed feedback to the patients regarding the drug’s efficacy and toxicity based on the
individual responses to the drug. As such, patient-specific iPSC-based drug screening and testing provide accurate genotype-to-phenotype correlation
that results in precise drug discovery and reduces the stressful and costly trial-and-error process for the patients, not to mention significantly reducing
the cost of health care.
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but there is a potential for individualized treatment free of
ethical concerns.
VI. Cancer Therapy–Induced
Cardiotoxicity Screening
From 1953 to 2013, 14% of the drugs were withdrawn
from market due to serious cardiovascular adverse
events (Onakpoya et al., 2016). These include a number
of cancer drugs and therapies reported to cause adverse
cardiovascular side effects, leading to CM damage and
heart failure, arrhythmias, hypertension, and coronary
artery disease (Lenneman and Sawyer, 2016) (Fig. 4).
The current approach to testing pre-market compounds
is not effective in gauging patient-specific responses
(Magdy et al., 2018). The use of patient-specific iPSCs in
drug safety testing and screening will thus be critical in
advancing these approaches (Sayed et al., 2019).
A. Doxorubicin-Induced Cardiotoxicity
The anthracycline antibiotic doxorubicin is one of
the oldest, yet most effective anticancer agents. Doxo-
rubicin is used to treat a wide range of malignancies,
including 50% to 60% of breast cancer and 70% of
childhood cancer treatment protocols. However, since
the use of doxorubicin began, the presence of a dose-
dependent complication of cardiotoxicity has been recog-
nized (Vejpongsa and Yeh, 2014; Yeh and Chang, 2016).
Doxorubicin-induced cardiotoxicity (DIC) is classed as
acute, developing immediately during treatment; chronic,
developing within the 1st year; or late-onset, occurring
up to 10 years after treatment (Zamorano et al., 2016).
Cardiotoxicity can range from asymptomatic reductions
in left ventricular ejection fraction to symptomatic heart
failure (New York Heart Association class III to IV).
These patients often make poor heart transplant candi-
dates because of their history of cancer (Shakir andRasul,
2009). The dose-dependent cardiotoxicity of doxorubicin
is well established (Lefrak et al., 1973; Von Hoff et al.,
1979). Initial reports documented the highest risk forDIC
at doses above ;450 mg/m2. With improved methods of
detecting subtle changes in cardiac function, the inci-
dence of DIC is now thought to bemuch higher, occurring
in up to 65% of long-term survivors of breast cancer, even
at doses as low as 228 mg/m2 (Kremer et al., 2002;
Swain et al., 2003). A study of three anthracycline
trials found subclinical cardiotoxicity in patients rather
than true latency between drug exposure and onset of
symptoms (Grenier and Lipshultz, 1998; Swain et al.,
2003). Furthermore, several studies have now shown
that asmany as 16%of childrenwith these abnormalities
will develop subsequent clinical heart failure with a
mortality rate as high as 72% (Lefrak et al., 1973; Felker
et al., 2000; Lipshultz et al., 2008).
Despite more than 50 years of research, the genetic
and molecular mechanisms of DIC remain unclear
(Vejpongsa and Yeh, 2014; Abe et al., 2016; Yeh and
Chang, 2016). To date, three major inter-related mech-
anisms for cardiotoxic effects of doxorubicin have been
proposed as follows: 1) generation of reactive oxygen
species and subsequent membrane damage; 2) inhibi-
tion of topoisomerase II-b (TOP2B) and topoisomerase I
mitochondrial; and 3) modulation of intracellular cal-
cium release. iPSC-CMs from DIC patients have been
used to recapitulate the phenotype and elucidate the
molecular mechanisms of the drug’s adverse effects
Fig. 4. Cardiotoxic effects of cancer therapies. Although a number of targeted and untargeted cancer therapies have shown efficacy in cancer
treatment, these therapies also cause cardiotoxic effects that can result in profound cardiovascular complications. Chemotherapies, including
anthracyclines such as doxorubicin, tyrosine kinase inhibitors, Her2-targeted therapies, and proteosome inhibitors, are associated with vascular
dysfunction and CM damage that can lead to heart failure. Platinum-based therapies, microtubule inhibitors, and radiation therapy have also been
linked to arrhythmias and pericardial disease. The pathobiology or the disease mechanisms of such cardiotoxic effects of various cancer therapies have
not been elucidated and must be addressed in a patient-specific manner.
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(Magdy et al., 2018). iPSC-CMs from healthy controls,
breast cancer patients who received doxorubicin treat-
ment without cardiotoxic side effects, and breast cancer
patients with DIC symptoms were generated, and their
transcriptomic profiles and functional differences were
compared (Burridge et al., 2016). Upon doxorubicin
treatment, iPSC-CMs of doxorubicin-sensitive patients
displayed sarcomeric disarray, arrhythmic beating, and
increased rate of apoptosis in comparison with control
iPSC-CMs. Doxorubicin-sensitive iPSC-CMs also showed
significantly increased reactive oxygen species levels after
24 hours of doxorubicin treatment, as indicated by in-
creased levels of whole-cell hydrogen peroxide and anti-
oxidant glutathione, a cellular oxidative stress response
marker. RNA-seq of iPSC-CMs from the three patient
groups showed a significant increase in expression
levels of program cell death and p53 downstream
pathway genes.
To develop effective therapeutics to treat DIC, it is
necessary to fully elucidate the underlying genetic and
molecularmechanisms of the drug’s side effects on CMs.
Previous studies demonstrated that the susceptibility of
TOP2B to select its target genes is dynamicallymodulated
by treatment of doxorubicin (Zhang et al., 2012). These
results led to a hypothesis that TOP2B is a key regulator
of DIC and is differentially regulated in doxorubicin-
sensitive and nonsensitive patients. However, the un-
derlying mechanisms by which TOP2B distributes to
chromatin and transcriptionally regulates specific tar-
get genes are still unidentified. Using the iPSC-CMs
generated fromthedoxorubicin-sensitive andnonsensitive
patients, a combination of techniques such as RNA-seq,
chromatin immunoprecipitation-seq, transposase-
accessible chromatin-seq, and immunoprecipitation–
mass spectrometry can be employed to determine the
role of TOP2B in transcriptional regulation of its target
genes, such as CTCF, RAD21, and DINO (Uusküla-
Reimand et al., 2016) in DIC patient-specific iPSC-
CMs (Fig. 5).
B. Tyrosine Kinase Inhibitor–Induced Cardiotoxicity
The development of small-molecule TKIs has led to
a dramatic increase in life expectancy for cancer
patients suffering from leukemias, carcinomas, and
melanomas. TKIs inhibit the kinase phosphorylation
activity of hyperactive receptor tyrosine kinases,
thereby halting the enhanced cell survival, prolifera-
tion, and migration phenotypes that are hallmarks of
cancer progression. However, several TKIs are linked
to severe cardiovascular side effects (Moslehi and
Deininger, 2015; Herrmann, 2016). Similar to DIC,
the mechanism of TKI-driven cardiotoxicity remains
poorly understood.
Currently, more than 80 TKIs are in development,
with cancer being themajor clinical indication. The first
TKI approved was imatinib, followed by erlotinib, sor-
afenib, sunitinib, dasatinib, lapatinib, nilotinib, gefitinib,
pazopanib, axitinib, and bosutinib. Sunitinib, sorafenib,
and ponatinib target the VEGF receptor and have been
noted to induce hypertension, arterial occlusions, and
venous thromboembolisms (Eskens and Verweij, 2006)
by adversely affecting ECs (Chu et al., 2007) and
pericytes (Chintalgattu et al., 2013). Whereas preclinical
screening with animal models is not able to accurately
identify the TKIs that cause cytotoxicity, the iPSC
technology overcomes this limitation by providing
patient-specific CMs and vascular cells en mass.
Notably, a high-throughput screening of 21 TKIs on
iPSC-CMs showed that nilotinib and crizotinib led to
the highest level of cytotoxicity, whereas sunitinib and
erlotinib generated the least degree of adverse cellular
effects to CMs (Sharma et al., 2017). CM impedance
assays have similarly been used to screen for TKIs with
high cardiotoxic potential (Peters et al., 2015). Lamore
et al. (2017) reported 30 of 65 TKIs investigated affected
CM contraction by regulating expression of genes re-
lated to calcium flux and action potential duration. By
taking into account various functional parameters of
iPSC-CMs obtained from the high-throughput screening,
a cardiac safety index can be generated and used as a
predictive quantitative metric for patient-specific cardio-
toxicity of TKIs (Sharma et al., 2018). Using iPSC-derived
vascular cells, the exact effects and patient-specific mech-
anisms of TKIs on hypertension and vasculopathies
should be investigated in future studies.
C. Human Epidermal Growth Factor Receptor
Inhibitor–Induced Cardiotoxicity
Human epidermal growth factor receptor–targeted
therapies such as trastuzumab, pertuzumab, and
lapatinib have shown a great promise in manage-
ment of breast cancer and are generally well-tolerated
(Florido et al., 2017). Trastuzumab therapy has
nonetheless been reported to elicit cardiotoxicity by
decrease in left ventricular ejection fraction with or
without clinical diagnosis of heart failure, which
manifests during the course of treatment with the
potential of reversibility in cardiac dysfunction when
withdrawn (Ewer et al., 2005). In vitro treatment of
clinically relevant doses of trastuzumab to iPSC-CMs
caused significant impairment in contractility and
calcium handling of the iPSC-CMs, but not cytotoxic
effects or disorganization of the sarcomeres reported
to be triggered by anthracycline treatment (Kitani
et al., 2019). The study has furthermore elucidated
that trastuzumab led to mitochondrial dysfunction
by altering cardiac energy metabolic pathways. In-
terestingly, iPSC-CMs generated from breast can-
cer patients with trastuzumab-induced cardiotoxicity
were shown to be more vulnerable to trastuzumab
therapy with decreased contractility and impaired
oxygen consumption and autophagy activity, un-
derlying a possibility of genetic predisposition for
trastuzumab-induced cardiotoxicity. Recent findings
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have ben shown metformin, an anti-diabetic medica-
tion, can render cardioprotective effects by activat-
ing AMP-activated protein kinase (AMPK) signaling
(Gundewar et al., 2009; Yin et al., 2011), suggesting
a potential repurposing of metformin as a prevention
or treatment of trastuzumab-induced cardiac dys-
function in patients with cancer. As such, patient-
specific iPSC-CMs can provide important clues to
cellular and molecular differences in cardiotoxicity
induced by different classes of chemotherapeutic
agents. Future studies using iPSC platform are
necessary to elucidate the potential cardioprotection
by concurrent treatment of conventional heart failure
medications with trastuzumab, such as b-blockers or
renin-angiotensin inhibitors (Bosch et al., 2013;
Pituskin et al., 2017).
VII. Therapeutics for Cardiac Disease
A. Arrhythmia
Dronedarone, the de-iodinated derivative of amiodar-
one, was touted as having all the beneficial effect of
amiodarone without the associated toxicities (Connolly
et al., 2011). The Dronedarone Versus Amiodarone for
the Maintenance of Sinus Rhythm in Patients with
Atrial Fibrillation trial (Le Heuzey et al., 2010), how-
ever, found that dronedarone was not as efficacious as
amiodarone at keeping patients in sinus rhythm. For
maintenance of sinus rhythm, dronedarone was found
to be equivalent to sotalol or flecanide. Promising post
hoc analysis from ATHENA (Hohnloser et al., 2009)
suggested that dronedarone could prevent cerebrovas-
cular accidents, but the composite of cerebrovascular
accidents, acute coronary syndrome, and cardiovascular
death was conclusively refuted in the ANDROMEDA
and PALLAS trials (Connolly et al., 2011), which clearly
showed that dronedarone was associated with more
thrombotic events and adverse events in heart failure
and chronic atrial fibrillation (Køber et al., 2008).
Dronedarone thus failed to live up to its billing as
a rhythm control medication equally efficacious to
amiodarone (Touboul et al., 2003; Singh et al., 2007;
Davy et al., 2008); moreover, dronedarone was found to
be deleterious by resulting in heart failure and chronic
Fig. 5. Elucidating mechanisms of doxorubicin-induced cardiotoxicity. Doxorubicin has shown cardiotoxicity for some patients. The patient-specific
disease mechanisms of doxorubicin-induced cardiotoxicity remain poorly understood, and the direct and indirect effects of doxorubicin on CMs have not
been clarified. Previous studies demonstrated that susceptibility of TOP2B to its target genes is dynamically modulated by doxorubicin. Using iPSC-
derived CMs from doxorubicin-sensitive and nonsensitive patients, the transcriptional machinery of TOP2B can be determined by combining
chromatin immunoprecipitation-seq, RNA-seq, transposase-accessible chromatin-seq, and immunoprecipitation–mass spectrometry. Cross-analysis of
RNA-seq and chromatin immunoprecipitation-seq will further allow identification of direct target genes of TOP2B, which can be confirmed by
chromatin immunoprecipitation-seq of TOP2B in human heart tissue. Verification of cardiac-specific target genes of TOP2B will lead to effective
patient-specific therapeutics to combat doxorubicin-induced cardiotoxicity.
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atrial fibrillation and was in no way superior to anti-
coagulation for preventing thromboembolic events (Køber
et al., 2008; Le Heuzey et al., 2010; Connolly et al., 2011).
Drugs like dronedarone cost billions of dollars to
develop and test in expensive clinical trials. Preclinical
testing with iPSC-CMs and cardiac organoids could
have averted the resulting financial catastrophe. Com-
bined with multiple electrode array, atrial-specific iPSC-
CMs and engineered heart tissues can now be used to
tailor drug therapy for individual patients (Laksman
et al., 2017; Lee et al., 2017a; Lemme et al., 2018).
Avoiding the iterative process of finding optimal
medical therapy for atrial fibrillation with reduced
cost to society will help more patients earlier and
reduce their morbidity and mortality. Indeed, iPSC-
based technology represents a significant improvement
in our ability to tailor drug therapy in a notoriously
difficult to manage population that accounts for approx-
imately $10,100 to $14,200 in the United States from
data compiled from 1990 to 2010 (Wolowacz et al., 2011).
Moreover, using the iPSC-based platforms, new targets
for drug therapy can be discovered for atrial fibrillation
(Devalla et al., 2015; Cyganek et al., 2018). Unlike animal
models that exhibit vastly different heart rates from
humans, iPSC-based cardiovascular platforms reflect
the human physiologic heart rate, increasing the
likelihood of translational success of compounds un-
der testing.
B. Cardiomyopathy
Cardiomyopathy is defined as a weakness of the heart
muscle. Cardiomyopathy patients suffer from dyspnea,
edema, and renal failure and succumb to pump failure
or sudden cardiac death if medical and device therapy is
not implemented with disease progression (Braunwald,
2017). In the absence of ischemic or valvular causes,
cardiomyopathies are broadly categorized into dilated,
restrictive, hypertrophic, or arrhythmogenic right ven-
tricular cardiomyopathy. The mechanisms of nonische-
mic cardiomyopathies are largely unknown, although
recent studies suggest that single-nucleotide poly-
morphisms may contribute to the development of
these cardiomyopathies (Hershberger et al., 2018).
Despite reductions in symptoms, hospital admissions,
and mortality, medical therapy for cardiomyopathy
has suffered from a dearth of new drug development.
Dilated cardiomyopathy (DCM) has been attributed
to mutations in sarcomere and sarcolemma-related
genes, including titin, lamin A/C (LMNA), MHC, and
cardiac troponins (Buikema and Wu, 2017). For in-
stance, Lee et al. (2019a) showed iPSC-CMs from DCM
patients with mutations in LMNA gene displayed
calcium-handling dysfunction, leading to arrhythmic
phenotype at the single-cell level. The study further
reported aberrant activation of PDGF-signaling pathway
in mutant iPSC-CMs to be responsible for the pathologic
phenotype, which is rescued by pharmacological and
molecular inhibition of PDGF receptor B. In iPSCs de-
rived from an independent proband of LMNA-associated
DCM, Siu et al. (2012) found pharmacological inhibition of
ERK1/2 pathway with mitogen-activated protein kinase
kinase 1/2 inhibitors to attenuate proapoptotic phenotype
of DCM iPSC-CMs.
Hypertrophic cardiomyopathy (HCM) is an abnormal
thickening of the ventricle that causes microinfarction,
outflow tract obstruction, and scarring, resulting in
arrhythmias (Marian and Braunwald, 2017). Patients
have symptoms of chest pain, dyspnea, and syncope,
and sometimes sudden cardiac death. A recent study
found that a premature stop codon in MYBPC3 leads to
HCMvia chronic activation of nonsense-mediated decay
(Seeger et al., 2019). Using CRISPR technology, iso-
genic mutation-corrected iPSC lines were generated to
serve as a control to HCM patient-derived iPSCs. Com-
parison of the mutant and isogenic control lines showed
that HCM iPSC-CMs display abnormal calcium-handling
properties without haploinsufficiency of MYBPC3, sug-
gesting that early pathophysiological processes at the
molecular level may precede the disease development.
Recently, Wu et al., 2019a reported novel methods to
measure impaired diastolic dysfunction by a combina-
tion of calcium imaging and traction force microscopy
in various familial HCM lines that carry mutations
in MYH7, MYBPC3, and TNNT2 genes. Simultaneous
recording of calcium transient and contractile stress by
functional imaging showed elevated diastolic intracel-
lular calcium levels and enhanced myofilament cal-
cium sensitivity in HCM iPSC-CMs in comparison with
those from healthy donors or DCM patients. The study
furthermore showed calcium channel blockers such
as verapamil and dilitiazem and late sodium channel
blockers such as ranolazine and electlazine can reequi-
librate calcium homeostasis and partially restore di-
astolic function in HCM iPSC-CMs. In another study,
bulk RNA sequencing of iPSC-CMs from healthy donors
and HCM patients after chronic exposure of four
individual calcium channel blockers (nifedipine, amlodi-
pine, dilitiazem, and verapamil) elucidated the patient-
specific and drug-specific transcriptomic signatures,
suggesting that the individual response may be related
to ability to compensate for the inhibition on calcium
entry (Lam et al., 2019). In addition, Jaffré et al. (2019)
showed aberrant ERK5 and mitogen-activated protein
kinase kinase 1/2 signaling pathways to be responsible
for RAF1-associated Noonan syndrome–induced HCM.
As such, the use of CRISPR gene editing andmultimodal
sequencing techniques in iPSCs has become a powerful
tool in directly evaluating the pathogenic role of a muta-
tion or a variant in cardiomyopathies (Musunuru et al.,
2018).
Development of therapies for left ventricular non-
compaction (LVNC), a condition increasingly recognized
as a cause of cardiomyopathy especially in children, is
also in dire need. Characterization of iPSC-CMs from
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LVNC patients carrying a mutation in cardiac transcrip-
tion factor TBX20 has shown that abnormal activation of
TGF-b signaling leads to defects in proliferation of CMs
(Kodo et al., 2016). Another investigation of familial
LVNC patients underlined the contribution of NKX2-5
variant as a genetic modifier of LVNC in conjunction
of missense mutations in MYH7 and MKL2 genes,
confirmed by genome-edited mouse models and patient-
derived iPSC-CMs (Gifford et al., 2019). The data
presented in these studies suggest a need for develop-
ment of therapeutics that simultaneously target all
pathologic variants to effectively treat complex genetic
diseases such as LVNC. Generation of cardiac-specific
fibroblasts from human iPSCs will also be critical in
assessing patient-specific pathophysiology of cardiac
fibrosis that occurs in tissue-ablating conditions, such
as ischemic cardiomyopathy (Zhang et al., 2019a). As
such, with improved understanding of the mecha-
nisms of cardiomyopathies and advancement in high-
throughput screening techniques, patient-specific iPSCs
will continue to prove valuable in screening for novel
therapeutics that reverse the disease phenotype and
ameliorate cardiac function.
C. Regenerative Medicine
The use of iPSCs for cardiovascular regenerative
medicine provides a limitless source of patient-specific
cells that can repair and/or even replace damaged
organs (Abou-Saleh et al., 2018; Chien et al., 2019).
iPSCs are considered autologous and believed to not
require immunosuppression, and gene editing can re-
verse disease phenotype by correction of the pathogenic
mutation or the variant. Nonetheless, translating
iPSC regenerative therapy from bench to clinical
practice faces many hurdles, one of which is that
the mass generation of iPSC-derived cells requi-
res significant time and cost. iPSC-derived cells
also exhibit batch variability and lack cellular
maturity.
Consequently, FDA approval would likely require
that iPSC-derived cell therapy fully address the issues
of arrhythmogenicity, tumorigenicity, and immunoge-
nicity (Neofytou et al., 2015). Continued advances in
biomaterial and tissue engineering may enable
iPSC-derived cardiovascular tissue to better circum-
vent these challenges in regenerative medicine applica-
tions (Huang et al., 2018).
VIII. Therapeutics for Vascular Disease
A. Atherosclerosis
In both primary and secondary prevention studies,
statins are the cornerstone of medical therapy. By
lowering cholesterol, statins have been effective in re-
ducing cardiovascular events and improving survival.
Numerous clinical trials in secondary prevention have
described the dose-dependent reductions in LDL levels,
correlated with improved survival (Ridker et al., 2008).
The emergence of proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitors has made it possible to further
lower LDL (Sabatine et al., 2017).
Although statin and PCSK9 therapies strive to lower
cholesterol levels, inflammation also plays a significant
role in the pathophysiology of cardiovascular disease.
The CANTOS trial revealed that the anti–interleukin-
1b antibody Canakinumab could further reduce car-
diovascular death and mortality beyond optimal
treatment with existing medical management that
includes the use of statins and PCSK9 inhibitor
(Ridker et al., 2017).
iPSC-based drug screens may identify novel drugs
that can target cholesterol biosynthesis. For example,
the iPSC-derived hepatocyte-like cells have been used
to study cardiac glycosides as an approach to reduce
hepatocyte production of apolipoprotein B and conse-
quently to treat hypercholesterolemia (Cayo et al., 2017).
Moreover, iPSC-ECs and iPSC-vSMCs can be used to
model atherosclerosis and test the efficacy of drugs that
target the inflammatory changes associated with endo-
thelial dysfunction and plaque formation.
B. Hypertension
Stage I hypertension is defined by systolic blood
pressure .130 mm Hg or a diastolic pressure .80 mm
Hg, and stage II hypertension with a systolic pressure
.140 mm Hg or a diastolic.90 mm Hg (Whelton et al.,
2018). The Antihypertensive and Lipid-Lowering Treat-
ment to PreventHeart Attack Trial study demonstrated
the importance of lowering blood pressure and reducing
cardiovascular risk by using appropriate medications
(ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group: The Antihypertensive
and Lipid-Lowering Treatment to PreventHeart Attack
Trial, 2002). The study did allow the caveat that un-
derlying comorbidities may direct drug therapy, such as
using an adrenocortical extract inhibitor in the con-
text of diabetes and concomitant hypertensive dis-
ease. Patients often requiremore than one hypertensive
agent to control their blood pressure (Jamerson et al.,
2008). Patient-specific differences can explain why
individuals respond to medications differently.
Hypertension is a disease primarily of the vascular
wall, and therefore iPSC-derived vascular cells may be
helpful in identifying new targets and developing new
drug therapies for this condition (Biel et al., 2015).
Moreover, iPSC platforms could be used to test these
compounds and to tailor therapy to the individual to
avoid the costly and inefficient iterative process of trial
and error otherwise required for finding the optimal
antihypertensive regimen.
C. Aortopathy
Aortopathy is a progressive disease of the vessel wall
that results in cystic medial necrosis and aneurysm or
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rupture of the vessel over time (Liddicoat et al., 1975).
The aorta is normally an elastic structure, but defects in
collagen synthesis and connective tissue can make the
vessel more susceptible to shear stress from blood
ejected from the heart. Traditionally, aortopathies are
managed with b-blockers that reduce shear stress on
the aorta. Studies using mouse models had suggested
that inhibitors of TGF-b signaling could help delay
the progression of Marfan syndrome (Neptune et al.,
2003). Marfan syndrome patient-derived iPSC-vSMCs
recapitulated the clinical phenotype in vitro and con-
firmed the critical role of TGF-b signaling in regula-
tion of proliferation and apoptosis of aortic vSMCs
(Granata et al., 2017). An independent study reported
transcriptomic analysis that showed Marfan syndrome
patient-derived iPSC-vSMCs to be more synthetic and
less contractile than the wild-type counterpart (Park
et al., 2017). Angiotensin receptor blockers were found
to be superior in mice (Habashi et al., 2006). However,
the overall outcome of the clinical trial was negative,
highlighting the overarching problem with mouse mod-
els that do not translate into viable clinical therapies
(Lacro et al., 2014).
The progression of aortopathy to dilatation, aneu-
rysm, and possible rupture makes regenerative therapy
a welcome option to surgery, either planned or emer-
gent, which is associated with significant morbidity and
mortality. iPSC-vSMCs can thus be used to discover
new biomarkers of aortopathy, which are expensive and
difficult to detect without serial imaging. Using an
iPSC-vSMC array, it may be possible to develop new
small molecular inhibitors of central medial necrosis
that is pathogenomic for aortopathy. Furthermore, to
best reflect the physiologic function and region-specific
blood flow hemodynamics in aortopathic conditions, it is
necessary to develop a vascular surrogate system that
cocultures iPSC-derived vascular, stromal, and immune
cell types under atheroprone hemodynamics. Such efforts
are currently under development to model changes in
hemodynamics and response to vascular inflammation
or drug treatments using iPSC-derived vascular cells
(Collado et al., 2017).
IX. Therapeutics for Cardiometabolic Disease
Cardiometabolic diseases and vasculopathies stem
from a combination of factors, including environmental
exposure, stress, smoking, poor diet, andmicrobiome, in
addition to genetic predisposition, requiring additional
layers of investigation to address the patient-specific
disease mechanisms (Fig. 6). Most prominently, type 2
diabetes (T2D) is a global epidemic affecting over 400
million people and is a leading cause of morbidity and
mortality (Menke et al., 2015). The prevalence of T2D is
increasing as obesity and sedentary lifestyle are becoming
more common in developing countries. The United States
has the highest lifetime health care costs associated
with T2D, reaching an estimated average of $283,000
per patient.
The primary cause for mortality in diabetic patients
is cardiovascular disease (Haffner et al., 1998). T2D is
associated with myocardial contractile dysfunction
through accelerated atherosclerosis, diabetic cardiomy-
opathy, and sudden cardiac death. T2D is due to insulin
resistance, an impaired response of the body to insulin
despite hyperinsulinemia (Malik et al., 2004), as well
as the failure of the pancreas to secrete adequate insulin
for glucose homeostasis. Insulin resistance can pre-
cede the onset of T2D and is commonly referred to as
prediabetes (Reaven, 2012).
Insulin resistance is associated with a metabolic
syndrome that includes hypertension and dyslipide-
mia. Insulin resistance is often undiagnosed because
it is difficult to test, but, like T2D, it is associated with
an increased risk of cardiovascular disease (Reaven,
2012). In addition to requiring more insulin for glucose
homeostasis, insulin resistance affects endothelial func-
tion. Nitric oxide release is impaired and is hypothe-
sized to be a precursor of atherosclerosis (Arcaro et al.,
2002; Kearney, 2013). Diabetes and insulin resistance
are polygenic disease (Brown and Walker, 2016). iPSCs
can serve as a renewable source of vascular tissue to
study the mechanisms of insulin resistance and to find
new personalized therapies that prevent cardiovascu-
lar disease in diabetic and insulin-resistant patients.
For further details on the use of human iPSCs for
pancreatic b-cell differentiation and regenerative ther-
apy, we refer the readers to this review (Shahjalal
et al., 2018).
T2D patients may also develop heart failure in-
dependent of these complications in a condition called
diabetic cardiomyopathy, which was first documented
in diabetic patients with adverse myocardial struc-
tural changes in the absence of hypertension and
vascular dysfunction (Haffner et al., 1998). The exact
mechanisms by which hyperglycemia induces dia-
betic cardiomyopathy are not fully understood, and
current clinical management does not specifically
address diabetes-induced heart failure (Jia et al.,
2016). As such, resolving the contributing mecha-
nisms of diabetic cardiomyopathy is a pressing goal
of basic and translational research. iPSC-CMs offer
an ideal platform to investigate the mechanisms of
diabetic cardiomyopathy and develop new therapeu-
tic targets, as studies have already shown that the
in vitro exposure of iPSC-CMs to persistent insulin
in the absence of glucose can mimic the physiologic
diabetic cardiomyopathy conditions (Drawnel et al.,
2014). The sodium-glucose transport protein 2 in-
hibitor, empagliflozin, was recently found to improve
cardiovascular outcomes, including heart failure.
This study showed that high glucose and insulin
increased sodium-glucose transport protein 2 expres-
sion and treatment with empagliflozin ameliorated
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cardiac dysfunction (Ng et al., 2018). In addition, a self-
organizing, human iPSC-derived three-dimensional
blood vessel organoid model was developed to model
structural and functional characteristics of dia-
betic microvasculopathy (Wimmer et al., 2019b).
Exposure of the organoids to hyperglycemia and
inflammatory cytokines to mimic the diabetic con-
ditions resulted in vascular basement membrane
thickening and splitting without increasing the ves-
sel diameter, which was rescued when treated with
g-secretase inhibitor DAPT. Development of such
iPSC-based organoid systems holds promise in ad-
vanced patient-specific disease modeling and drug
screening and testing for diabetic cardiomyopathy
and vasculopathies.
X. Concluding Remarks
Cardiovascular drug discovery is enormously chal-
lenging due to factors such as the unavailability of
cardiac cells, combinatorial etiology of cardiovascular
diseases, and imperfect translation of animal studies to
human subjects. Combined with the state-of-the-art
tools in multiomics analysis (Wirka et al., 2018; Lau
et al., 2019), the advent of iPSC technology has been
pivotal in overcoming these limitations by providing
a platform to better understand the patient-specific
disease mechanisms and help to discover new person-
alized therapeutics.
However, a number of challenges in the use of iPSC
technology for cardiovascular disease modeling and
drug screening remains to be resolved. These include
the generation of adult-like and tissue-specific sub-
types of iPSC-derived cardiovascular cells as well as
development of methods to introduce nongenetic etiolog-
ical factors, all of which are currently under intensive
investigation. Because the multifaceted pathophysiology
of cardiovascular diseases involves multiple cell types in
a number of organ systems, in vivo model validation is
necessary to delineate the comprehensive disease phe-
notype, which should be performed concurrently to verify
the findings from the iPSC-based in vitro studies. In
addition, it will be necessary to generate functional and
physiologic three-dimensional cardiac organoids and
to develop high-throughput platforms utilizing heart
and vessel mimics to enable effective and accurate
drug screening and testing.
Notwithstanding these challenges, continuing advan-
ces have made the use of patient-specific iPSCs an
indispensable and powerful tool in the discovery of
effective therapeutics for all cardiovascular diseases,
helping to realize the full potential of cardiovascular
precision medicine.
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